Discovery Life Sciences’ Post

Today, we are celebrating a series of groundbreaking advancements that mark the start of a new era for Discovery. The official opening of our brand-new state-of-the-art facilities in Huntsville, AL, and Alameda, CA, the launch of revolutionary Olink Explore HT services, and our revitalized website together will amplify our ability to empower scientists on a global scale.    "This trifecta of advancements signifies a profound moment in our journey," said Discovery CEO Glenn Bilawsky. "From Alameda to Huntsville, from the physical to the digital, we're reshaping the future of life sciences. We're more equipped than ever to catalyze innovations that have the potential to transform lives."  - Glenn Bilawsky, CEO of Discovery Life Sciences Visit our new website to learn more: https://lnkd.in/gHr-CZZ2

In recognition of the upcoming National Social Media Day on June 30th, we celebrate the power of social media in connecting people, ideas, and opportunities around the world. Today, we acknowledge the impact of platforms like LinkedIn in fostering professional relationships, sharing knowledge, and driving innovation. We recently reached 20,000 followers on LinkedIn - a testament to our commitment to connecting with all of you. We express our gratitude to our followers, partners, and colleagues around the world for supporting us on this digital journey. Your engagement, insights, and support have played a pivotal role in our success, and we are grateful for this vibrant community that continues to grow around our shared passion for advancing the development of innovative therapies and diagnostics. Let's continue this journey together! Your feedback, collaborations, and contributions are invaluable to us. Stay tuned for more exciting updates and insights from the world of Discovery Life Sciences. 

Discovery’s SpecimenSeq™ FFPE and Double-Spun Plasma (DSP) Matched Sets are trusted by liquid biopsy researchers for verifying biomarker targets, driver mutations, and clinically significant genomic variants. This inventory covers 2,000+ variants from 50+ clinically relevant genes across 30 oncology indications and 300+ unique patients. Supplies are limited, so reserve your SpecimenSeq™ FFPE and DSP Matched Sets today: https://lnkd.in/gyymRC6k #LiquidBiopsy #NGS #OncologyResearch 

Discovery proudly celebrates Juneteenth—the day that marks the end of slavery in America and the freedom of all Americans. Today and every day, we strive for inclusion and racial equality and seek to become better allies to our Black and African American friends and colleagues. Let’s keep the conversation going and work together towards a more equitable future for everyone.  #juneteeth #blacklivesmatter #freedom 

In a recent interview with Life Sciences Review, Jay Scherer, Discovery’s Chief Operating Officer, shared how our Science at Your Service philosophy enables our clients to ignite breakthroughs in precision medicine.    Read the article: https://lnkd.in/gSVvctJR Discovery is deeply committed to helping researchers worldwide advance therapies and improve patient outcomes. During his interview, Jay mentions that, “our team members and customers often share personal incidents of health challenges. These stories remind us that there is a patient with hope behind every sample we provide.” We believe each biospecimen sample and every service we provide could hold the key to the next significant medical breakthrough.  #PrecisionMedicine #Biospecimens #DrugDevelopment

Join us next week for an exciting webinar hosted by Agilent! Discovery’s Executive Vice President of Pathology and Medical Affairs, Dr. Hans-Ulrich Schildhaus, will moderate the conversation and share insights on HER2 testing.  Register today: https://lnkd.in/e3g854pr

We are proud to announce the opening of our new office and laboratory facility in Malden, MA. This new facility will house Discovery’s renowned Gentest® in vitro preclinical products and services, along with a new clean room and cell processing laboratory to enhance our AllCells® GMP offerings on the East Coast. Read the press release to learn more:  https://lnkd.in/g78mbViY “Our new Malden facility underscores our commitment to advancing therapeutic solutions that significantly improve patient outcomes,” said Discovery’s CEO Greg Herrema. “By expanding our footprint in the Greater Boston area in response to growing customer demand, we enhance our capacity to deliver cutting-edge cell and gene therapy solutions that drive impactful drug discovery and development.” Join our journey as Discovery continues to grow and help accelerate the discovery and development of new therapies and diagnostics. 

In recognition of Alzheimer's & Brain Awareness Month, we are excited to highlight novel research that could pave the way for new neurological treatments for diseases like Alzheimer's. A recent publication from Scripps Research Institute has identified new proteins involved in Alzheimer's progression. Utilizing a novel single-cell patch-clamp/proteomics platform, researchers analyzed the electrical patterns and protein levels of individual neurons. They discovered nearly 50 proteins that are differentially expressed in Alzheimer's neurons compared to healthy ones. These findings open exciting avenues for follow-up studies to investigate the potential of these proteins as new drug targets to treat or slow Alzheimer's disease.  https://lnkd.in/gyjcxGSF   #ENDALZ #Proteomics 

Request a quote today and get 20% off with promo code "Match20". https://lnkd.in/gkfE9fTw